补肺通窍汤治疗气虚血瘀型持续性变应性鼻炎的临床研究及对肥大细胞类胰蛋白酶的影响

发布时间：2019-01-07 09:45

【摘要】：目的：通过补肺通窍汤治疗气虚血瘀型持续性变应性鼻炎的临床研究,观察其临床疗效、安全性；通过肥大细胞类胰蛋白酶的变化,探讨补肺通窍汤的作用机制。方法：选取成都中医药大学附属医院的门诊持续性变应性鼻炎(气虚血瘀型)患者60例,随机分组,其中试验组30例口服补肺通窍汤免煎配方颗粒；对照组30例口服开瑞坦,疗程均15天。健康者30例,作为健康组。医治期间,观察及记录两组患者的临床症状及体征,以调查问卷的方式记录生活质量积分,并记录不良反应,采用ELISA方法检测收集3组血清样本中的肥大细胞类胰蛋白酶的表达情况,对获得的数据,应用SPSS19.0软件进行统计学处理和分析治疗结果。结果：本研究试验组与对照组医治第7天的总有效率分别为33.33%、46.43%,两组相比无显著性差异(P0.05),治疗第7天试验组与对照组的流涕症状具有显著性差异(P0.05),对照组优于试验组。医治15天后的总有效率分别为81.48%、71.43%,两组相比无显著性差异(P0.05)。组间相比,二者的症状、体征、咳嗽痰稀及生活质量经医治后无显著性差异(P0.05)；组内相比上述症状均具有显著性差异(P0.05),且试验组的自汗症状有显著性差异(P0.05)。变应性鼻炎(气虚血瘀型)患者的MC T表达水平均高于健康组,差异有统计学意义(P0.05)；试验组医治后,MC T表达水平下降,差异有统计学意义(P0.05)；对照组医治后,MC T表达水平下降,差异有统计学意义(P0.05)：试验组及对照组医治后,差异无统计学意义。结论：1.试验组(补肺通窍免煎颗粒)与对照组(开瑞坦)均能改善持续性变应性鼻炎(气虚血瘀型)患者的症状、体征及生活质量,二者疗效相当,治疗7天,对照组的流涕症状优于试验组。2.MCT在持续性变应性鼻炎(气虚血瘀型)的发病过程中升高,经治疗后降低,可通过MC T的变化,为临床上应用补肺通窍汤有效治疗变应性鼻炎提供试验依据。3.补肺通窍汤免煎颗粒临床使用安全,目前未发现明显的毒副作用。
[Abstract]:Objective: to observe the clinical efficacy and safety of Bufei Tongqiao decoction in the treatment of chronic allergic rhinitis with Qi deficiency and blood stasis, and to explore the mechanism of Bufei Tongqiao decoction through the change of mast cell trypsin. Methods: sixty patients with persistent allergic rhinitis (qi deficiency and blood stasis type) were randomly divided into two groups. The control group (30 cases) were treated with Kelitan for 15 days. 30 healthy patients were used as healthy group. During the course of treatment, the clinical symptoms and signs of the two groups were observed and recorded. The quality of life score was recorded by questionnaire, and the adverse reactions were recorded. ELISA method was used to detect the expression of mast cell trypsin in three groups of serum samples. The data obtained were statistically processed and the results of treatment were analyzed by SPSS19.0 software. Results: the total effective rate of treatment on the 7th day in the study group and the control group was 33.33 ~ 46.43 and there was no significant difference between the two groups (P0.05). On the 7th day of treatment, the symptoms of snot in the experimental group and the control group were significantly different (P0.05), and the control group was superior to the experimental group. After 15 days of treatment, the total effective rate was 81.48 and 71.43, respectively. There was no significant difference between the two groups (P0.05). There was no significant difference in symptoms, signs, cough, phlegm and quality of life between the two groups after treatment (P0.05). Compared with the above symptoms, there were significant differences between the two groups (P0.05), and there were significant differences in the self-sweating symptoms in the experimental group (P0.05). The expression level of MC T in allergic rhinitis (qi deficiency and blood stasis type) was higher than that in healthy group (P0.05), and the, MC T expression level in experimental group decreased after treatment (P0.05). The level of, MC T expression in the control group decreased after treatment, the difference was statistically significant (P0.05): the experimental group and the control group after treatment, the difference was not statistically significant. Conclusion: 1. The symptoms, signs and quality of life of the patients with persistent allergic rhinitis (Qi deficiency and blood stasis type) were improved in both the experimental group (Bufei Tongqiao decoction granule) and the control group (Kelitan group). The symptoms of snot in the control group were better than those in the experimental group. 2.MCT increased during the onset of persistent allergic rhinitis (qi deficiency and blood stasis type), decreased after treatment, and could be changed through the change of MC T. To provide experimental evidence for clinical application of Bufei Tongqiao decoction in the treatment of allergic rhinitis. 3. Bufei Tongqiao decoction is safe in clinical use, and no obvious side effects have been found at present.
【学位授予单位】：成都中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R276.1

【相似文献】